Intellia Therapeutics Ends Co-Development Agreement With Regeneron
By Chris Wack
Intellia Therapeutics said in a filing that it has notified Regeneron Pharmaceuticals that it is opting out of its Factor IX co-development and co-funding agreement, which Intellia and Regeneron entered into in May 2020.
The agreement will end 180 days after Intellia's written notice to Regeneron, and the company will continue to have obligations related to the co-development of gene-editing products directed to Factor IX until the effective date of termination.
Upon termination, Intellia will no longer be obligated for sharing 35% of the development costs, or be entitled to receive 35% of the profits, for gene-editing products.
Intellia will continue to support Regeneron with the development of gene-editing products under a previous license and collaboration agreement.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 22, 2024 10:23 ET (14:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing